H
067630
vs
K
KOSPI 200
Over the past 12 months, HLB Life Science Co Ltd has underperformed KOSPI 200, delivering a return of -60% compared to the KOSPI 200's +98% growth.
Stocks Performance
067630 vs KOSPI 200
Performance Gap
067630 vs KOSPI 200
Performance By Year
067630 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HLB Life Science Co Ltd
Glance View
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.